Allergan, Inc. announced the U.S. Food and Drug Administration’s (FDA) approval of JUVÉDERM(R) XC, a new formulation of the currently FDA-approved JUVÉDERM(R) dermal filler and the latest advancement in hyaluronic acid (HA) dermal fillers. Allergan’s new JUVÉDERM(R) formulation contains the local anesthetic lidocaine to provide patients with enhanced comfort during treatment of moderate to severe facial wrinkles and folds, such as the nasolabial folds (or “parentheses”) that appear around the nose and mouth. JUVÉDERM(R) is the first and only hyaluronic acid dermal filler approved by the FDA to last up to one year from initial treatment and number-one selling hyaluronic acid dermal filler.
“As the global leader in medical aesthetics, Allergan is committed to providing the latest scientific advancements in facial aesthetic products to meet patients’ demands and further optimize their experiences,” said Robert Grant, Allergan’s Corporate Vice President and President, Allergan Medical. “We lead innovation in the dermal filler category with the first and only smooth-consistency gel hyaluronic acid dermal filler approved by the FDA to last up to a year. Now we have added lidocaine to JUVÉDERM(R) to provide the same smooth, long-lasting result, but with additional comfort for patients.”
The JUVÉDERM(R) XC formulation with 0.3% preservative-free lidocaine numbs the treatment area within seconds, potentially reducing the need for an additional anesthetic. JUVÉDERM(R) XC provides the same smooth, long-lasting results as demonstrated with existing formulations of JUVÉDERM(R), and now offers a more comfortable injection experience and potentially less time spent in the physician’s office when compared to the non-lidocaine JUVÉDERM(R) formulation.
“Patients want a smooth and natural-looking result from a dermal filler treatment, but as a physician I am also interested in managing my patient’s discomfort during the injection. Before the introduction of JUVÉDERM(R) XC it often took up to 30 minutes for an anesthetic block to take effect. In the clinical trial leading up to the FDA approval, patients reported they experienced less pain with JUVÉDERM(R) XC, compared to their previous dermal filler treatment without lidocaine. So with the new formulation, patients can receive the same smooth results as demonstrated with JUVÉDERM(R) but enjoy a more comfortable injection experience,” said Charles Boyd, M.D., Boyd Cosmetic Surgical Institute and JUVÉDERM(R) XC clinical investigator.